Evidence map›Paper›PMID 25356594›Full record

ArticlePloS one2014

Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Fausto Titti, Maria T Maggiorella, Flavia Ferrantelli, Leonardo Sernicola, Stefania Bellino, Barbara Collacchi, Emanuele Fanales Belasio, Sonia Moretti, Maria Rosaria Pavone Cossut, Roberto Belli and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Fausto TittiNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Maria T MaggiorellaNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Flavia FerrantelliNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Leonardo SernicolaNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Stefania BellinoNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Barbara CollacchiNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Emanuele Fanales BelasioNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Sonia MorettiNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Maria Rosaria Pavone CossutNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Roberto BelliNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Erika OlivieriNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Stefania FarcomeniNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Daniela CompagnoniNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Zuleika MicheliniNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Michela SabbatucciNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Katia SparnacciDepartment of Environmental and Live Science, University of East Piemonte, Alessandria, Italy.
Luisa TondelliI.S.O.F., Consiglio Nazionale delle Ricerche, Bologna, Italy.
Michele LausDepartment of Environmental and Live Science, University of East Piemonte, Alessandria, Italy.
Aurelio CafaroNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Antonella CaputoDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Barbara EnsoliNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Istituto Superiore di Sanità · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITBologna Research Area · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we describe a prime-boost regimen of vaccination in Macaca fascicularis that combines priming with novel anionic microspheres designed to deliver the biologically active HIV-1 Tat protein and boosting with Tat in Alum. This regimen of immunization modulated the IgG subclass profile and elicited a balanced Th1-Th2 type of humoral and cellular responses. Remarkably, following intravenous challenge with SHIV89.6Pcy243, vaccinees significantly blunted acute viremia, as compared to control monkeys, and this control was associated with significantly lower CD4+ T cell depletion rate during the acute phase of infection and higher ability to resume the CD4+ T cell counts in the post-acute and chronic phases of infection. The long lasting control of viremia was associated with the persistence of high titers anti-Tat antibodies whose profile clearly distinguished vaccinees in controllers and viremics. Controllers, as opposed to vaccinated and viremic cynos, exhibited significantly higher pre-challenge antibody responses to peptides spanning the glutamine-rich and the RGD-integrin-binding regions of Tat. Finally, among vaccinees, titers of anti-Tat IgG1, IgG3 and IgG4 subclasses had a significant association with control of viremia in the acute and post-acute phases of infection. Altogether these findings indicate that the Tat/H1D/Alum regimen of immunization holds promise for next generation vaccines with Tat protein or other proteins for which maintenance of the native conformation and activity are critical for optimal immunogenicity. Our results also provide novel information on the role of anti-Tat responses in the prevention of HIV pathogenesis and for the design of new vaccine candidates.

Indexed as

Drug Delivery SystemsMicrospheresAcquired Immunodeficiency SyndromeAIDS VaccinesAnimalsAnionsAntibody FormationBiocompatible MaterialsCD4-Positive T-LymphocytesCross-PrimingCytokinesEpitope MappingImmunity, CellularImmunity, HumoralImmunizationImmunoglobulin GAIDS VaccinesAnionsBiocompatible MaterialsCytokinesImmunoglobulin GPolymerstat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID25356594
PMCPMC4214729
OpenAlexW2040852693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.